Evidence map›Paper›PMID 27168803›Full record

ArticleExperimental and therapeutic medicine2016

Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C.

Motoyuki Kohjima, Miho Kurokawa, Munechika Enjoji, Tsuyoshi Yoshimoto, Tsukasa Nakamura, Tomoko Ohashi, Kunitaka Fukuizumi, Naohiko Harada, Yusuke Murata, Kazuhisa Matsunaga and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Motoyuki KohjimaDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Miho KurokawaDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Munechika EnjojiFaculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Tsuyoshi YoshimotoDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Tsukasa NakamuraDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Tomoko OhashiDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Kunitaka FukuizumiDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Naohiko HaradaDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.
Yusuke MurataFaculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Kazuhisa MatsunagaFaculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Masaki KatoDepartment of Medicine and Bioregulatory Science, Kyushu University, Fukuoka 812-8582, Japan.
Kazuhiro KotohDepartment of Medicine and Bioregulatory Science, Kyushu University, Fukuoka 812-8582, Japan.
Makoto NakamutaDepartment of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1% at days 3 and 7, appearing similar regardless of baseline renal function. Urinary β

Indexed as

HCVinterferonrenal dysfunctionribavirintelaprevir

Identifiers

PMID27168803
PMCPMC4840744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.